Salicornia, which is colloquially known as ‘sea asparagus,’ is rapidly emerging as a transformative solution for future food ...

Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the ...

Pasithea Therapeutics Corp. ( KTTA) Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 4:00 PM EST ...

The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca’s diversified IP portfolio for RAS-driven cancers Initial Phase 1 ...

By Hugo Francisco de Souza New research suggests that zinc does far more than support immunity, revealing intricate molecular switches that may influence how the heart responds to inflammatory injury.

The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase 1 ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...

The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...

CRVS stock surged more than 200% in early 2026 as investors repriced its oral ITK inhibitor opportunity. Erasca Inc (ERAS) secured $258.8 million in fresh capital and holds patent protection on ...

Scientists at Duke-NUS Medical School have identified a molecular "switch" that determines whether pancreatic cancer cells resist chemotherapy or respond to it—a finding that could help convert some ...

Deep in our cells, a wide range of processes are occurring constantly. These cellular processes rely on enzymes to act as catalysts and set off a series of molecular interactions. There are still many ...

A secondary stress signaling pathway in the response to optic axon injury is an unexpectedly strong contributor to both neurodegeneration and axon regenerative potential.